UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: May 2023
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant’s name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
On May 1, 2023, Akari Therapeutics, Plc (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2022, as well as highlights on recent clinical progress.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The statements under “Full Year 2022 Highlights and Recent Updates” and “Full Year 2022 Financial Results” of Exhibit 99.1 are hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Akari Therapeutics, Plc |
| | (Registrant) |
| | |
| | By: | /s/ Rachelle Jacques |
| | Name: | Rachelle Jacques |
| | Title: | President and Chief Executive Officer |
Date: May 1, 2023
